TY - JOUR
T1 - Combined antiangiogenic and mammalian target of rapamycin inhibitor targeted therapy in metaplastic breast cancer harboring a PIK3CA mutation
AU - Agarwal, Rishi
AU - Koenig, Kimberly
AU - Rohren, Eric
AU - Subbiah, Vivek
N1 - Publisher Copyright:
© 2014 Korean Breast Cancer Society. All rights reserved.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Metaplastic breast cancer (MpBC) is an extremely rare breast cancer subtype, characterized by a heterogeneous phenotype. MpBC aggressive biology is attributed to its stem cell-like characteristics. Since these tumors are largely chemoresistant, novel targeted therapies should be explored. Herein, we report the clinical course of a 59-year-old African American woman with MpBC with a PIK3CA mutation in codon 545, exon 10 (GAG to AAG; p.Glu545Lys) and a TP53 mutation in codon 286, exon 8 (GAA to AAA; p.Glu286Lys). The same mutations were observed in the primary and secondary sites. The patient was treated with a molecularly matched therapy using a combined antiangiogenic and mammalian target of rapamycin kinase inhibitor strategy that included liposomal doxorubicin, bevacizumab, and temsirolimus. Partial remission was achieved. In this report, the scientific rationale underlying the activity of this combination was explored. In conclusion, patients may benefit from being offered molecular profiling early during the course of the disease to receive a therapy guided accordingly.
AB - Metaplastic breast cancer (MpBC) is an extremely rare breast cancer subtype, characterized by a heterogeneous phenotype. MpBC aggressive biology is attributed to its stem cell-like characteristics. Since these tumors are largely chemoresistant, novel targeted therapies should be explored. Herein, we report the clinical course of a 59-year-old African American woman with MpBC with a PIK3CA mutation in codon 545, exon 10 (GAG to AAG; p.Glu545Lys) and a TP53 mutation in codon 286, exon 8 (GAA to AAA; p.Glu286Lys). The same mutations were observed in the primary and secondary sites. The patient was treated with a molecularly matched therapy using a combined antiangiogenic and mammalian target of rapamycin kinase inhibitor strategy that included liposomal doxorubicin, bevacizumab, and temsirolimus. Partial remission was achieved. In this report, the scientific rationale underlying the activity of this combination was explored. In conclusion, patients may benefit from being offered molecular profiling early during the course of the disease to receive a therapy guided accordingly.
KW - Bevacizumab
KW - Breast neoplasms
KW - PIK3CA protein
KW - Tumor suppressor protein p53
UR - http://www.scopus.com/inward/record.url?scp=84923373522&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923373522&partnerID=8YFLogxK
U2 - 10.4048/jbc.2014.17.3.287
DO - 10.4048/jbc.2014.17.3.287
M3 - Article
C2 - 25320628
AN - SCOPUS:84923373522
SN - 1738-6756
VL - 17
SP - 287
EP - 290
JO - Journal of Breast Cancer
JF - Journal of Breast Cancer
IS - 3
ER -